These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Paraoxonase enzyme activity is enhanced by zinc supplementation in hemodialysis patients. Rahimi-Ardabili B; Argani H; Ghorbanihaghjo A; Rashtchizadeh N; Naghavi-Behzad M; Ghorashi S; Nezami N Ren Fail; 2012; 34(9):1123-8. PubMed ID: 22950600 [TBL] [Abstract][Full Text] [Related]
10. [Relation between paraoxonase activity, other HDL components and inflammatory state in hemodialyzed patients]. González AI; Brites F; Elbert A; Gómez-Rosso L; Berg G; Wikinski R; Schreier L Medicina (B Aires); 2010; 70(6):508-12. PubMed ID: 21163737 [TBL] [Abstract][Full Text] [Related]
11. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Shimoike T; Inoguchi T; Umeda F; Nawata H; Kawano K; Ochi H Metabolism; 2000 Aug; 49(8):1030-5. PubMed ID: 10954022 [TBL] [Abstract][Full Text] [Related]
12. Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation--are they inter-related? Sebeková K; Podracká L; Heidland A; Schinzel R Clin Nephrol; 2001 Dec; 56(6):S21-6. PubMed ID: 11770807 [TBL] [Abstract][Full Text] [Related]
13. Effect of nandrolone decanonate on paraoxonase activity in hemodialysis patients. Ghorbanihaghjo A; Argani H; Rahbaninoubar M; Rashtchizadeh N Clin Biochem; 2005 Dec; 38(12):1076-80. PubMed ID: 16153628 [TBL] [Abstract][Full Text] [Related]
15. Soluble receptor for advanced glycation end products in patients with decreased renal function. Kalousová M; Hodková M; Kazderová M; Fialová J; Tesar V; Dusilová-Sulková S; Zima T Am J Kidney Dis; 2006 Mar; 47(3):406-11. PubMed ID: 16490618 [TBL] [Abstract][Full Text] [Related]
17. Clearance of increased serum advanced glycosylation end products in patients with end stage renal disease by hemodialysis. Liu NF; Sun ZL; Liu BC Acta Pharmacol Sin; 2000 Mar; 21(3):276-80. PubMed ID: 11324431 [TBL] [Abstract][Full Text] [Related]
18. Paraoxonase 1 arylesterase activity and mass are reduced and inversely related to C-reactive protein in patients on either standard or home nocturnal hemodialysis. Kannampuzha J; Darling PB; Maguire GF; Donnelly S; McFarlane P; Chan CT; Connelly PW Clin Nephrol; 2010 Feb; 73(2):131-8. PubMed ID: 20129020 [TBL] [Abstract][Full Text] [Related]
19. Oxidative stress and high-density lipoprotein function in Type I diabetes and end-stage renal disease. Kalogerakis G; Baker AM; Christov S; Rowley KG; Dwyer K; Winterbourn C; Best JD; Jenkins AJ Clin Sci (Lond); 2005 Jun; 108(6):497-506. PubMed ID: 15634192 [TBL] [Abstract][Full Text] [Related]
20. Advanced glycation end product free adducts are cleared by dialysis. Agalou S; Ahmed N; Thornalley PJ; Dawnay A Ann N Y Acad Sci; 2005 Jun; 1043():734-9. PubMed ID: 16037300 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]